Skip to main content
. 2020 Dec 16;14(8):1908–1914. doi: 10.1093/ckj/sfaa231

FIGURE 1:

FIGURE 1:

Patient and kidney allograft survival after belatacept treatment. (A) Kaplan–Meier estimate of patient survival was similar in HIV-positive kidney allograft recipients converted to belatacept compared with the control group of HIV-positive kidney allograft recipients treated with CNI (P = 0.38). (B) Kaplan–Meier estimate of kidney allograft survival, in HIV-positive kidney allograft recipients converted to belatacept compared with the control group of HIV-positive kidney allograft recipients treated with CNI (P = 0.36). (C) eGFR and proteinuria evolution after belatacept conversion. eGFR increased significantly 3 and 12 months after belatacept conversion (P = 0.01 and P = 0.009, respectively). Proteinuria tended to decrease at 3 months (P = 0.08), which is no longer observed at 12 months (P = 0.22).